Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CS-3150 on QTc Interval in Healthy Subjects
NCT04019652Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esaxerenone in hypertension (HTN) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in corrected QT (QTc) interval from baseline following oral administration of CS-3150. Started Nov 2015; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04019652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019652.